Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hymenistatin 1 SCHEMBL25456477 | 1.00 | HDAC8 (0.51) | HDAC8 | |
| Axinastatin 5 SCHEMBL8569878 | 0.98 | HDAC8 (0.48) | HDAC8 | |
| SCHEMBL29349704 | 0.96 | HDAC8 (0.54) | HDAC8 | |
| SCHEMBL29711638 | 0.93 | ABCB1 (0.53) | — | |
| SCHEMBL29711439 | 0.93 | ABCB1 (0.52) | — | |
| Cyclolinopeptide A SCHEMBL31609181 | 0.91 | ABCB1 (0.54) | — | |
| Phakellistatin 12 SCHEMBL2353639 | 0.89 | ABCB1 (0.51) | — | |
| SCHEMBL29711614 | 0.89 | ABCB1 (0.51) | HDAC8 | |
| SCHEMBL32676347 | 0.87 | PSMB11 (0.53) | — | |
| SCHEMBL29220474 | 0.87 | ABCB1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220401560-A1 | PEPTIDE ENCAPSULATING FERRITIN | AJINOMOTO CO., INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| EP-4056233-A1 | FERRITIN ENCLOSING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2022-09-14 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114341156-A | Ferritin encapsulated with peptides | 味之素株式会社 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | HDAC8 846/4885 |
| US-20220401560-A1 | PEPTIDE ENCAPSULATING FERRITIN | FTH1, SLC40A1, TFRC | HDAC8 4554/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | HDAC8 1604/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | HDAC8 846/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | HDAC8 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.